The main aim of our study was to investigate the evolution of the mutational profile of HR+ HER2- BC relapsing during or after the completion of adjuvant ET following surgical resection, with or without (neo)adjuvant chemotherapy. The gene discussed is ERBB2; the disease is breast cancer.